CDMO
GP Pharm specialises in the research, development, and production of injectable pharmaceuticals. Particularly noteworthy is our company's extensive experience in the development and manufacture of pharmaceutical products based on extended-release drug systems: microspheres, liposomes, lipid nanoparticles, and micellar solutions.
GP Pharm's research and development laboratories have the most innovative technologies that, together with a highly qualified team, allow the development and manufacture of a wide spectrum of products, successfully executing the different projects of our company. GP Pharm offers its expertise to other companies through its Contract Development and Manufacturing Organisation (CDMO) department.
Our company is open to establishing collaborations with other companies interested in GP Pharm's development and manufacturing capabilities.
Services
GP Pharm is authorised for the manufacture of investigational, preclinical, validation, and injectable solutions and lyophilised pharmaceutical products.
In addition, our industrial plant and quality system comply with the requirements of Annex 13 of the cGMP, which allows the manufacture of clinical batches.
Which products?
Sterile bulk injectable and packaged pharmaceuticals, based on:
- Cytotoxic active ingredients.
- High potency active ingredients (HPAPIs) such as peptides, oligonucleotides, hormones, etc.
- Active ingredients with intermediate potency.
- Buffer and/or reconstitution solutions.
- Extended-release drug systems: microspheres, liposomes, and micellar solutions.
What kind of dosages?
- Vials
- Blisters
- Prefilled syringes
- Pens
Which formulations?
- Liquids
- Lyophilised